Research press release


Nature Medicine

Getting a TALEN-hold on mitochondrial disease



この目標をよりうまく達成するために、Carlos Moraesたちは、特異的なTALEN(転写アクチベーター様エフェクターヌクレアーゼ)を作製した。TALENは、目的とする任意のDNA配列に結合するよう改変できる酵素である。彼らの作ったTALENはミトコンドリアに入り、ヒトの病気に関係する2種類の変異mtDNAを特異的に認識して切断した。次にMoraesたちは、これらの変異をもつ培養ヒト細胞でこのTALENを使うと、変異mtDNA量が減少するとともに、エネルギー生産能力が正常に回復することを明らかにした。


A more specific method for deleting mutant mitochondrial DNA in human cells in order to combat diseases associated with mitochondrial dysfunction is reported in a paper published this week in Nature Medicine. These results may eventually be useful in permanently treating patients with some mitochondrial diseases.

The mitochondria-organelles that supply energy for all human cells-have their own genomic DNA (mtDNA). Deleterious mutations in mtDNA can be inherited or built up over time, leading to reduced mitochondrial function and disease. Previous work has looked at selectively eliminating mutant mtDNA while sparing normal mtDNA as a way to permanently treat such diseases.

To better achieve this goal, Carlos Moraes and his colleagues have created specific transcription activator-like effector nucleases (TALENs), which are enzymes that can be engineered to bind to any DNA sequence of interest. Their TALENs enter mitochondria and uniquely recognize and cleave two different mutant mtDNAs associated with human disease. The authors next showed that use of their TALENs reduced the levels of mutant mtDNA in cultured human cells harboring these mutations, as well as restoring the normal energy-producing capacity of these cells.

Though in vivo validation and other technical hurdles will need to be overcome before such an approach can be used in the clinic, Moraes and colleagues note that life-long treatment with the TALENs is likely not needed as once a cell has eliminated most if not all of its mutant mtDNA, then the cell and its progeny are ‘cured’.

doi: 10.1038/nm.3261


メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週各ジャーナルからの最新の「注目のハイライト」をまとめて皆様にお届けいたします。